Gilead abandons phase 3 study of magrolimab for myelodysplastic syndromes
Sundry Photography/iStock Editorial via Getty Images                 
Gilead Sciences (NASDAQ:GILD) has decided to end a phase 3 study of magrolimab for higher-risk myelodysplastic syndromesÂ due to futility.
The anti-CD47 immunotherapy is continuing to be evaluated in other pivotal trials for acute myeloid leukemia and in earlier stages for other cancer types.

More on Gilead Sciences

Gilead: Assessing How Shares Will Trade Over Upcoming Months (Technical Analysis)
Gilead Sciences: An Evolving Biopharma Navigating Through Challenges And Opportunities